Tweeting for Health Using Real-time Mining and Artificial Intelligence-Based Analytics: Design and Development of a Big Data Ecosystem for Detecting and Analyzing Misinformation on Twitter.

BACKGROUND: Digital misinformation, primarily on social media, has led to harmful and costly beliefs in the general population. Notably, these beliefs have resulted in public health crises to the detriment of governments worldwide and their citizens. However, public health officials need access to a comprehensive system capable of mining and analyzing large volumes of social media data in real time. OBJECTIVE: This study aimed to design and develop a big data pipeline and ecosystem (UbiLab Misinformation Analysis System [U-MAS]) to identify and analyze false or misleading information disseminated via social media on a certain topic or set of related topics. METHODS: U-MAS is a platform-independent ecosystem developed in Python that leverages the Twitter V2 application programming interface and the Elastic Stack. The U-MAS expert system has 5 major components: data extraction framework, latent Dirichlet allocation (LDA) topic model, sentiment analyzer, misinformation classification model, and Elastic Cloud deployment (indexing of data and visualizations). The data extraction framework queries the data through the Twitter V2 application programming interface, with queries identified by public health experts. The LDA topic model, sentiment analyzer, and misinformation classification model are independently trained using a small, expert-validated subset of the extracted data. These models are then incorporated into U-MAS to analyze and classify the remaining data. Finally, the analyzed data are loaded into an index in the Elastic Cloud deployment and can then be presented on dashboards with advanced visualizations and analytics pertinent to infodemiology and infoveillance analysis. RESULTS: U-MAS performed efficiently and accurately. Independent investigators have successfully used the system to extract significant insights into a fluoride-related health misinformation use case (2016 to 2021). The system is currently used for a vaccine hesitancy use case (2007 to 2022) and a heat wave-related illnesses use case (2011 to 2022). Each component in the system for the fluoride misinformation use case performed as expected. The data extraction framework handles large amounts of data within short periods. The LDA topic models achieved relatively high coherence values (0.54), and the predicted topics were accurate and befitting to the data. The sentiment analyzer performed at a correlation coefficient of 0.72 but could be improved in further iterations. The misinformation classifier attained a satisfactory correlation coefficient of 0.82 against expert-validated data. Moreover, the output dashboard and analytics hosted on the Elastic Cloud deployment are intuitive for researchers without a technical background and comprehensive in their visualization and analytics capabilities. In fact, the investigators of the fluoride misinformation use case have successfully used the system to extract interesting and important insights into public health, which have been published separately. CONCLUSIONS: The novel U-MAS pipeline has the potential to detect and analyze misleading information related to a particular topic or set of related topics.

Non-COVID infections causing MIS-C in COVID recovered children: An association or co-illness - A case series.

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multi-system inflammatory syndrome (MIS-C) is being reported all across the world. Why some children develop it whereas others do not and the various implicating agents for the same are not clear. It has been seen that various infections are associated with immune mediated diseases. Whether new infections, in COVID recovered children, can lead to the cascade of MIS-C is still a matter of debate. We report a case series of four cases of MIS-C all subsequent after bacterial or viral infection in COVID recovered children. All children had a documented evidence of past SARS-CoV-2 infection and present bacterial or viral infection. They were given the required management as per the concerned infection but none improved after standard therapy. All children showed drastic improvement after initiation of specific therapy for MIS-C. It is important to understand increased risk of MIS-C with new onset viral and bacterial infections in COVID recovered children.

Effect of COVID-19 Necessitated Telephone-virtual Verses In-person Delivery of Obesity Care at VA Facility

Background: A vast majority of the VA population is either overweight or obese, which is a serious health concern. Obesity care has been traditionally delivered via in-person clinics. The COVID-19 pandemic forced the delivery of care to be switched to virtual platforms Methods: To study the effectiveness of in-person versus virtual (telephone only) delivery of obesity care, which included behavioral therapy and pharmacotherapy, an observational study was designed to include participants who were either newly enrolled or had previously established care at the VA Move! program in Minneapolis for weight management between the years of 2017 to 2021. These participants were divided into two groups. A transition cohort (obtained in-person care from March 2019 to March 2020, then transitioned to virtual care). A new start cohort (enrolled after March 2020 with virtual care);this group was compared to a separate historical group which obtained in-person care between January 2019 to December 2020. Weight loss was accessed over a 9-month period in both cohorts. Results: The mean weight loss over 9 months was -6.4±18.1 lbs and -2.5±13.3 lbs in the in-person and virtual phases of the transition cohort, respectively, without any significant difference between the two phases (p=0.22). The mean weight loss over 9 months in the new start (virtual) cohort was -14.4±17.0 lbs compared to -16.7±21.0 lbs in the historical cohort, without any significant difference between the two groups (p=0.44). Conclusions: Weight loss with virtual-telephone care was comparable to in-person care in our weight management program.

Ranking Methodology for Evaluating Region-Wise COVID-19 Testing Performance in India

For containment of COVID-19, most countries are following the isolate, test, treat and trace approach. Following the approach, India scaled up COVID-19 testing from about 5,000 tests per day at the end of March 2020 to more than 1 M tests per day in September 2020. Testing scale-up has seen a huge variation across states and union territories (UTs) with respect to growth rates, testing strategies, testing infrastructure, and deployment of various kit types (RT-PCR, Antigen, CBNAAT, etc). To understand the gaps in testing and prioritize appropriate interventions, it is important for national stakeholders to evaluate and rank states/UTs based on their testing performance. Indicators like total samples tested, total samples positive, tests per million, and positives per million are currently being used by epidemiologists and researchers for comparing the performance of various regions. This article proposes a robust ranking methodology to rank the states/UTs in India based on a comprehensive scoring developed by combining multiple variables for evaluating the testing performance of states/UTs. Since RT-PCR testing is considered the gold standard for COVID-19 testing, the composite score for testing performance in this article is defined by the ability of states/UTs to successfully deploy RT-PCR testing and reduce its positivity over time. Evaluating region-wise ranking can enable the identification of areas requiring immediate attention in poorly performing regions, thus channelizing efforts and resources in the right direction.

Consensus Guidelines on Opening Up of Aesthetic Practices in India During the COVID-19 Era.

INTRODUCTION: The COVID-19 is a pandemic which has affected most people directly or indirectly. It being a communicable disease, the best way to control the disease is to prevent its spread. Lockdown in India has resulted in aesthetic practices all over the country being shut down indefinitely. As things return to normal, most aesthetic practitioners are looking forward to opening practices. Hence, there was a definite need for a consensus on how to safely open up practices in India and at the same time reassure patients coming into these clinics that their safety is paramount. METHODS: This consensus guidelines use the PICO model in its structure. Five critical areas for opening up clinical establishments were identified and approached independently. A questionnaire was prepared using the modified Likert scale, and all the stakeholders were asked to answer the same. Any differences were then resolved with discussion among the stakeholders. The entire study was divided into five subgroups which were then analyzed in detail. RESULTS: Key recommendations and consensus guidelines were made after detailed analysis. Handy flow diagram reviews of these key areas have been provided. A thorough review of literature was also done on each of the critical areas and recommendations incorporated wherever feasible. CONCLUSION: These recommendations have considered the difficulties and cultural issues faced by aesthetic practices in India. They are user friendly, easy to understand and implement. These guidelines would help in reassuring practices to open up safely and continue serving patients with utmost care. LEVEL OF EVIDENCE: Level V, Consensus guidelines.

Acceptance and Preparedness to be COVID Warriors: Self Narratives of Frontline Nurses of a Tertiary Care Center.

AIM: Aim of this study is to gain insight into how frontline nurses accepted and prepared themselves before COVID posting. METHODS: It is a qualitative and phenomenological study design. Eighteen in-depth interviews were conducted with the nurses who provided care to confirmed COVID 19 patients in a tertiary hospital of North India from September to November 2020. The interviews were transcribed and analyzed using Colaizzi's phenomenological method. The consolidated criteria for reporting qualitative research (COREQ) were followed in this study. RESULTS: In this study, the reported experiences were divided into five main themes: (I) Getting ready to be at the frontlines (II) Family and peer support (III) I Can Handle it! (IV) I have to be Strong! (V) Training is key to confidence. The risk of infection, fear of being a source of infection to the family, the worry of staying away from family, uncertainty, and nervousness related to personal protective equipment were the most common thoughts that disturbed the participants. However, taking a good diet, practicing yoga and meditation, having a sense of serving their country and community, faith in God, family support, faith in the organization, and good training helped the participants to prepare for the COVID posting. CONCLUSION: Despite facing various challenges, the nurses showed great strength and resilience. To promote a resilient health system, supportive supervision and adequate administrative support, training and workshops, peer group support, counseling cells, and spiritual support may be considered.

Management of COVID-19 Pandemic Data in India: Challenges Faced and Lessons Learnt.

COVID-19 is an ongoing pandemic, which has already claimed millions of lives worldwide. In the absence of prior information on the pandemic, the governments can use generated testing data to drive policy decisions. Thus, a one-stop repository is essential to ensure sharing of clean, de-duplicated, and updated records to all the stakeholders. In India, the government initiated the testing through a network of VRDLs headed by the Indian Council of Medical Research (ICMR). Initially, the generated data were captured and shared in Excel sheets. As the number of cases increased, there was a need for a data management system to ensure reliable and up-to-date data to drive policy decisions. Thus, the data management team at ICMR initiated the development of a national COVID-19 testing data management tool that is currently maintaining all the data in a central hub. The first version of the tool was released in March 2020 and was subsequently modified with the changing testing guidelines and strategies. On completing one and a half years of managing the data and collecting approximately 550 million records, the team analyzed the challenges faced and the strategies used to ensure a seamless flow of data to the system and its real-time analysis. In this study, the entire duration of the pandemic has been divided into four different phases based on the resourcefulness of the country. Since the pandemic is currently ongoing, this study can be useful for countries in a different phase of pandemic facing similar challenges.

Anticipated pharmacological role of Aviptadil on COVID-19.

Vasoactive intestinal peptide (VIP) is a neuropeptide that is produced by the lymphoid cells and plays a major role in immunological functions for controlling the homeostasis of the immune system. VIP has been identified as a potent anti-inflammatory factor, in boosting both innate and adaptive immunity. Since December 2019, SARS-Cov-2 was found responsible for the disease COVID-19 which has spread worldwide. No specific therapies or 100% effective vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and several drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir, and tocilizumab. This paper describes the main pharmacological properties of synthetic VIP drug (Aviptadil) which is now under clinical trials. A patented formulation of vasoactive intestinal polypeptide (VIP), named RLF-100 (Aviptadil), was developed and finally got approved for human trials by FDA in 2001 and in European medicines agency in 2005. It was awarded Orphan Drug Designation in 2001 by the US FDA for the treatment of acute respiratory distress syndrome and for the treatment of pulmonary arterial hypertension in 2005. Investigational new drug (IND) licenses for human trials of Aviptadil was guaranteed by both the US FDA and EMEA. Preliminary clinical trials seem to support Aviptadil's benefit. However, such drugs like Aviptadil in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds.

Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update.

COVID-19 outburst initiated from the city of Wuhan in China in December 2019 and has been declared as a public health emergency of international concern. This pandemic portrays a spectrum of clinical complications, primarily affecting the respiratory system reported to be caused by a pathogen SARS-CoV-2 belonging to the family of beta coronavirus. Currently, the main objective of the government authorities of all affected countries and research organizations is to find a potential solution in the form of a pharmacological intervention or a vaccination to eradicate the disease and to have a long-term solution to deal with the pandemic. A multitude of anti-viral regimens is proposed based on the repurposing of currently available drugs for other issues or the compassionate use of drugs to immediately control and optimize the healthcare facilities. Meanwhile, a number of agencies are proposing new drug candidates to recreate the possibility of treating the disease. Similarly, a lot of research work is going on worldwide for the development of vaccination. Currently, a good number of candidates has finally reached the borders of Clinical Trials and are expected to be launched as soon as possible. However, the regulatory framework and authorization of these candidates is the most significant aspect of the whole scenario, which needs a specific set of time for validation purposes. The present work is widely focused on the general aspects of COVID-19 and the regulatory landscape for the emergency authorization of repurposed drug candidates, compassionate use of drugs, investigational entities, and vaccine development worldwide. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13337-021-00684-5.

Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.

To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001).

Loss of smell and taste in COVID-19 infection in adolescents.

OBJECTIVES: To study the prevalence, clinical course and outcomes of olfactory and taste dysfunction in COVID-19 positive adolescents. METHODS: This prospective study was carried out from May to August 2020. The adolescents, aged 10-19 years, who were detected COVID-19 positive by RT-PCR with mild to moderate disease were included in the study. The following epidemiological and clinical outcomes were studied: age, sex, general symptoms, olfactory and taste dysfunction. RESULTS: Out of 141 patients included in the study, there were 83 males (58.9%) and 58 females (41.1%). The age varied from 10 to 19 years with an average of 15.2 years. Forty patients (28.4%) had olfactory or taste dysfunction. Out of these 40 patients, 28 patients (19.8%) had both olfactory and taste dysfunction. Of the 34 patients (24.1%) who complained of olfactory dysfunction, 16 patients complained of hyposmia and 18 patients complained of anosmia. Dysgeusia was reported by 34 patients (24.1%). The duration of OTD varied from 2 to 15 days with an average of 5.7 days. CONCLUSION: Loss of smell and taste are common symptoms in COVID-19 positive adolescents. It recovers spontaneously within a few weeks, along with the resolution of other symptoms.

Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients?

OBJECTIVES: To evaluate the correlation between cycle threshold (Ct) value and occurrence of olfactory and taste dysfunction in COVID-19 patients. METHODS: This comparative study included COVID-19 patients diagnosed by reverse transcription- polymerase chain reaction (RT-PCR) based test at our hospital with mild to moderate disease. The demographic details and detailed clinical history of the patient, including history of loss of smell and taste was taken at the time of presentation. The patients were divided into 2 groups, group A: COVID-19 patients with OTD; group B: COVID-19 patients without OTD. 100 contiguous patients were recruited in each group. The COVID-19 test by RT-PCR was done and Ct value of the 3 genes: E (Envelope encoding) gene, N (Nucleocapsid encoding) gene, and RdRp (RNA-dependent RNA polymerase) gene, was used for data analysis. The Ct values of each of the three genes were compared between groups A and B. RESULTS: Group A and B did not differ significantly in terms of basic demographics. The differences in the Ct values of the 3 genes E gene, N gene and RdRp gene, of group A and B were found to be statistically significant (p = 0.005, p = 0.001 and p = 0.002, respectively). CONCLUSION: The patients with OTD had a lower Ct value at diagnosis, and hence, a higher viral load than those without OTD. The evaluation of Ct value and viral load in COVID-19 patients may help in further reducing the transmission of the virus in the community.

Anosmia: A Clinical Indicator of COVID-19 Reinfection.

COVID-19, an ongoing world pandemic, is caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Many organizations have recognized that COVID-19 patients may have sudden loss of smell or taste and have included these symptoms in their diagnostic guidelines. However, the occurrence of anosmia and dysgeusia in COVID-19 reinfection is yet to be ascertained.

Renal Transplant Recipient with Concurrent COVID-19 and Stenotrophomonas maltophilia Pneumonia Treated with Trimethoprim/Sulfamethoxazole Leading to Acute Kidney Injury: A Therapeutic Dilemma.

BACKGROUND Although coronavirus disease 2019 (COVID-19) manifests primarily as a lung infection, its involvement in acute kidney injury (AKI) is gaining recognition and is associated with increased morbidity and mortality. Concurrent infection, which may require administration of a potentially nephrotoxic agent, can worsen AKI and lead to poor outcomes. Stenotrophomonas maltophilia is a multidrug-resistant gram-negative bacillus associated with nosocomial infections, especially in severely immunocompromised and debilitated patients. Trimethoprim/sulfamethoxazole combination (TMP/SMX) is considered the treatment of choice but can itself lead to AKI, posing a significant challenge in the management of patients with concomitant COVID-19 and S. maltophilia pneumonia. CASE REPORT A 64-year-old male with end-stage renal disease and post renal transplant presented with severe respiratory symptoms of COVID-19 and was intubated upon admission. His renal functions were normal at the time of admission. The patient subsequently developed superimposed bacterial pneumonia with S. maltophilia requiring administration of TMP/SMX. However, TMP/SMX led to the development of AKI, which continued to worsen despite appropriate management including hemodialysis. This coincided with and most likely resulted in the patient's clinical deterioration and ultimate death. CONCLUSIONS The etiology of kidney disease involvement in patients with COVID-19 is still evolving and appears to be multifactorial. The condition can significantly worsen especially when nephrotoxic agents are given, probably due to a cumulative or synergistic effect. Great caution should be taken when administering nephrotoxic agents in the setting of COVID-19 as it can lead to adverse patient outcomes.